DNA damage-inducible transcript 3

Source: Wikipedia, the free encyclopedia.
DDIT3
Identifiers
Gene ontology
Molecular function
Cellular component
Biological process
Sources:Amigo / QuickGO
Ensembl
UniProt
RefSeq (mRNA)

NM_001290183
NM_007837

RefSeq (protein)

NP_001277112
NP_031863

Location (UCSC)Chr 12: 57.52 – 57.52 MbChr 10: 127.13 – 127.13 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

DNA damage-inducible transcript 3, also known as C/EBP homologous protein (CHOP), is a pro-

heterodimers with other C/EBP members, preventing their DNA binding activity. The protein is implicated in adipogenesis and erythropoiesis and has an important role in the cell's stress response. [6]

Structure

C/EBP proteins are known to have a conserved

C-terminal structure, basic leucine zipper domain(bZIP), that is necessary for the formation of DNA-binding capable homodimers or heterodimers with other proteins or members of the C/EBP protein family. [7] CHOP is a relatively small (29kDa) protein that differs from most C/EBP proteins in several amino acid substitutions, which impacts its DNA-binding ability. [8]

CHOP protein structure created with PyMOL

Regulation and function

Due to a variety of upstream and downstream regulatory interactions, CHOP plays an important role in

neurological diseases, and neoplastic
diseases.

Under normal physiological conditions, CHOP is ubiquitously present at very low levels.

apoptotic pathways in a wide variety of cells. [8] Those processes are mainly regulated by three factors: protein kinase RNA-like endoplasmic reticulum kinase (PERK), activating transcription factor 6 (ATF6), and inositol requiring protein 1 (IRE1α) [10][11]

Upstream regulatory pathways

During

ER stress, CHOP is mainly induced via activation of the integrated stress response pathways through the subsequent downstream phosphorylation of a translation initiation factor, eukaryotic initiation factor 2α (eIF2α), and induction of a transcription factor, activation transcription factor 4 (ATF4),[12] which converges on the promoters
of target genes, including CHOP.

Integrated stress response, and thus CHOP expression, can be induced by

Under ER stress, activated transmembrane protein ATF6 translocates to the nucleus and interacts with ATF/cAMP response elements and ER stress-response elements,[17] binding the promoters and inducing transcription of several genes involved in unfolded protein response (including CHOP, XBP1 and others).[18][19] Thus, ATF6 activates the transcription of both CHOP and XBP-1, while XBP-1 can also upregulate the expression of CHOP.[20]

ER stress also stimulates transmembrane protein IRE1α activity.[21] Upon activation, IRE1α splices the XBP-1 mRNA introns to produce a mature and active XBP-1 protein,[22] that upregulates CHOP expression[23][24][25] IRE1α also stimulates the activation of the apoptotic-signaling kinase-1 (ASK1), which then activates the downstream kinases, Jun-N-terminal kinase (JNK) and p38 mitogen-activated protein kinase (p38 MAPK),[26] which participate in apoptosis induction along with CHOP.[27] The P38 MAP kinase family phosphorylates Ser78 and Ser81 of CHOP, which induces cell apoptosis.[28] Moreover, research studies found that the JNK inhibitors can suppress CHOP upregulation, indicating that JNK activation is also involved in the modulation of CHOP levels.[29]

Downstream pathways

Apoptosis induction via Mitochondria-Dependent Pathway

As a transcription factor, CHOP can regulate the expression of many anti-apoptotic and

BAX, BOK, BIM, PUMA and others).[32][33]

Under ER stress, CHOP can function as either a

upregulate the expression of proapoptotic proteins (BIM, BAK and BAX expression).[35][36] BAX-BAK oligomerization causes cytochrome c and apoptosis-inducing factor (AIF) release from mitochondria, eventually causing cell death.[37]

TRB3 pseudokinase is upregulated by the ER stress-inducible transcriptional factor, ATF4-CHOP.[38] CHOP interacts with TRB3, which contributes to the induction of apoptosis.[39][40][41] The expression of TRB3 has a pro-apoptotic capacity.[42][43] Therefore, CHOP also regulates apoptosis by upregulating the expression of the TRB3 gene.

Apoptosis induction via Death-Receptor Pathway

caspase cascade to induce apoptosis.[44]

A summary of CHOP upstream and downstream pathways

The PERK-ATF4-CHOP pathway can induce

JUN to form a complex that regulates the expression of DR4 and DR5.[44] CHOP also upregulates the expression of DR5 by binding to the 5′-region of the DR5 gene.[45]

Under prolonged ER stress conditions, activation of the PERK-CHOP pathway will permit DR5 protein levels to rise, which accelerates the formation of the death-inducing signaling complex (DISC) and activates caspase-8,[46] leading to apoptosis[47]

Apoptosis induction through other downstream pathways

In addition, CHOP also mediates apoptosis through increasing the expression of the ERO1α (ER reductase)[10] gene, which catalyzes the production of H2O2 in the ER. The highly oxidized state of the ER results in H2O2 leakage into the cytoplasm, inducing the production of reactive oxygen species (ROS) and a series of apoptotic and inflammatory reactions.[10][48][49][50]

The

overexpression of CHOP can lead to cell cycle arrest and result in cell apoptosis. At the same time, CHOP-induced apoptosis can also trigger cell death by inhibiting the expression of cell cycle regulatory protein, p21. The p21 protein inhibits the G1 phase of the cell cycle as well as regulates the activity of pre-apoptotic factors. Identified CHOP-p21 relationship may play a role in changing the cell state from adapting to ER stress towards pre-apoptotic activity.[51]

Under most conditions, CHOP can directly bind to the

BAX expression, and increased Bcl-2 gene expression.[52] Bag5 overexpression inhibited ER stress-induced apoptosis in the unfolded protein response by suppressing PERK-eIF2-ATF4 and enhancing the IRE1-Xbp1 activity.[53]

In general, the downstream targets of CHOP regulate the activation of apoptotic pathways, however, the molecular interaction mechanisms behind those processes remain to be discovered.

Interactions

DNA damage-inducible transcript 3 has been shown to

interact
with [proteins]:

Clinical significance

Role in fatty liver and hyperinsulinemia

CHOP mediates beta cell ER remodeling

Chop gene deletion has been demonstrated protective against diet induced metabolic syndromes in mice.[60][61] Mice with germline Chop gene knockout have better glycemic control despite unchanged obesity. A plausible explanation for the observed dissociation between obesity and insulin resistance is that CHOP promotes insulin hypersecretion from pancreatic β cells.[62]

Furthermore, Chop depletion by a GLP1-ASO delievery system[63] was shown to have therapeutic effects of insulin reduction and fatty liver correction,[64] in preclinical mouse models.[62]

Role in microbial infection

CHOP-induced apoptosis pathways had been identified in cells infected by

Since CHOP has an important role of apoptosis induction during infection, it is an important target for further research that will help deepen the current understanding of pathogenesis and potentially provide an opportunity for invention of new therapeutic approaches. For example, small molecule inhibitors of CHOP expression may act as therapeutic options to prevent ER stress and microbial infections. Research had shown that small molecule inhibitors of PERK-eIF2α pathway limit PCV2 virus replication.[65]

Role in other diseases

The regulation of CHOP expression plays an important role in metabolic diseases and in some cancers through its function in mediating apoptosis. The regulation of CHOP expression could be a potential approach to affecting cancer cells through the induction of apoptosis.[51][29][44][74] In the intestinal epithelium, CHOP has been demonstrated to be downregulated under inflammatory conditions (in inflammatory bowel diseases and experimental models of colitis). In this context, CHOP seems to rather regulate the cell cycle than apoptotic processes.[75]

Mutations or fusions of CHOP (e.g. with

FUS-CHOP) can cause Myxoid liposarcoma.[49]

References

  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000175197Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000025408Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. PMID 1990262
    .
  6. ^ a b c "Entrez Gene: DDIT3 DNA-damage-inducible transcript 3".
  7. PMID 8657121
    .
  8. ^ .
  9. .
  10. ^ .
  11. .
  12. .
  13. .
  14. .
  15. .
  16. .
  17. .
  18. .
  19. .
  20. .
  21. .
  22. .
  23. .
  24. .
  25. .
  26. .
  27. .
  28. .
  29. ^ .
  30. .
  31. .
  32. .
  33. .
  34. .
  35. .
  36. .
  37. .
  38. .
  39. .
  40. .
  41. .
  42. .
  43. .
  44. ^ .
  45. .
  46. .
  47. .
  48. .
  49. ^ .
  50. .
  51. ^ .
  52. .
  53. .
  54. .
  55. ^ .
  56. .
  57. .
  58. .
  59. .
  60. .
  61. .
  62. ^ .
  63. AstraZeneca AB
     
  64. .
  65. ^ .
  66. .
  67. .
  68. .
  69. .
  70. .
  71. .
  72. .
  73. .
  74. .
  75. .

Further reading

External links

This article incorporates text from the United States National Library of Medicine, which is in the public domain.